Mineralys Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hey. Good morning, everyone, and welcome to the Mineralys Therapeutics session. Happy to have Jon Congleton, CEO of Mineralys, with us this morning. As you know, Mineralys is developing a new class, or has developed a new class of drugs, aldosterone synthase inhibitors, for uncontrolled and resistant hypertension. John, why don't you give a quick overview and the lay of the land, and we'll just launch into questions.
Yeah, happy to do it, and good to see you, Annabel, and thank you again to the Stifel team. Always enjoy the conference and the opportunity to talk about Mineralys. As you said, we're thrilled to be a part of a new class, aldosterone synthase inhibitors. As Annabel knows, I started my career as a sales rep in this space, and I've seen how transformative new treatments can be. Given the fact that about half of the treated patients in the U.S. cannot get to goal with currently available treatments, I think having innovations like aldosterone synthase inhibitors and lorundrostat are really critical. We've spent the last five-plus years, I think, building a very robust, diverse data set that went into our NDA about a year ago.
We are progressing towards our PDUFA date, December 22nd of this year, and have progressively built out a readiness to ensure that we have a successful launch going into 2027.
Great. Let's talk about that PDUFA date. December 22nd is obviously approaching very quickly, and you have a, I would say, a pretty impressive large trial package. How are you seeking to leverage that wealth of data that you have to support a differentiated label? Can you potentially get a differentiated label rather than just standard uncontrolled resistant hypertension?
Yeah. The PDUFA remains on track. I think if I think about the label, there are going to be some similarities and there will be some differences relative to what baxdrostat got this summer. The similarities are going to be the indication. It is for the treatment of inadequately controlled hypertension on top of background medications. There is also going to be a statement about reduced blood pressure, reduces the risk of stroke, MI, and cardiovascular disease. That is based on FDA guidance from 2012, and so that will look similar. Where the differences obviously come is in the body of the label, certainly section 14. We really efforted to create a data set that reflects the population that physicians are treating when they are treating hypertension, and there is a lot of variety. There is variety in gender, race, age, obviously, but there is also a lot of overlapping comorbidities.
The work that we did with our Explore programs, looking at the benefit of lorundrostat in patients with comorbid CKD, the OSA study, and comorbid OSA, obesity, how much of that will be reflected in the label will be known by December 22, 2026. But I think fundamentally, having that wealth of data is going to be important for the medical community to know how to incorporate lorundrostat into their treatment paradigm. We have different vectors to do that, right? We have the promotional team, sales and marketing. We have med affairs to disseminate publications and make sure that KOL interactions, they understand not only the data within the label, but just our broader data set and how to appropriately use lorundrostat.
Mm-hmm. When you think about the package that they have and the population that you have studied, where do you think physicians are going to be most comfortable using the drug first?
We have built a data set looking at patients failing two or more meds. So that is third line uncontrolled and fourth line resistant. I think the low-hanging fruit will be the fourth line, so the resistant hypertension population. It does not mean that we will not be promoting for both, but I think based on initial trial by physicians, initial access, fourth line is going to be the predominant area. As far as patient subtypes within that, again, I think that is where the diversity of the patient populations that we have for fourth line can speak to it very broadly. Case in point, Black African Americans are probably the highest risk population as far as most difficult to get to their respective goals. We had 29% and 53% of our two pivotal studies were Black or African American. So physicians do not have to presume that the drug is going to work across race.
We can show them the data and say, "Lorundrostat works equally well." That is important because there is variable response based on ethnicity. Having data, not only the Explore CKD study, but Launch-HTN, we presented a subset analysis of those patients with CKD. So really robust and meaningful reduction in blood pressure, reduction in UACR. It is these pockets of patients, and again, by physician type, primary care, cardiology, nephrology. I think we have really exquisite data sets to really speak to the specific patients they are seeing.
Can you just remind us what Baxfendy has as far as where they can position the drug in the marketplace?
Baxfendy, similar construct in the number of background meds. They looked at patients failing on two or more. Similar in that regard. Third line and fourth line is where they can position it. I think we have a little bit more diversity within our studies, both on gender and on race. I think just what has been published to date, a broader population, or broader background as far as comorbidities, things like OSA and obesity.
Okay, great. Maybe you can talk to us, okay, before we get into how you are going to launch this drug. Can you provide any color from any of the mid to late cycle stage meetings that you had with FDA? Like, any further requests post the 120-day safety update? What type of post-marketing requests might they make of you?
Yeah or have you do Yeah.
I will reiterate, December 22nd is where we are tracking to. I would characterize, because we have not really gotten into the details and specifics of where we are, but I would characterize it as kind of normal course. Again, you made the point, I think we have a very meaningful and robust data package that we were able to put into the NDA, very well characterized, and including EXPLORE-CKD in the lower eGFR population, giving a full picture of lorundrostat across the spectrum of hypertension. So, feel very confident in that December 22nd date.
Okay. Baxdrostat is launched already, Baxfendy. I guess without head-to-head data, or cross-trial comparisons between the two, how are you preparing to speak to physicians about, and maybe even the payers, to evaluate lorundrostat relative to what is available to them right now? Do you think that there is something that clearly distinguishes the two outside of just data? Are you expecting counter-detailing, or are you just planning to launch lorundrostat? Hopefully you get an easier name to say because it is killing me.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
